Pfizer has announced that the FDA has approved Xeljanz XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment...
Pfizer Inc. has announced that the FDA has approved Xeljanz XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily...
Pfizer announced that the FDA has approved the supplemental New Drug Application (sNDA) for Xeljanz / Xeljanz XR (tofacitinib) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
Pfizer Inc. announced positive results from ORAL Shift, a Phase IIIb/IV study in adult patients with moderately to severely active...
When Xeljanz XR (tofacitinib extended release) from Pfizer, was approved in 2016 the approval carried warnings of risk of serious...